Can Twist Bioscience (TWST) Stock Reach $200?

Key Takeaways

• The selected price target is $200, a round-number milestone that sits just below the stock's all-time high of roughly $214 set in January 2021.
• Twist Bioscience has been one of the market's standout performers, up more than 300% year-to-date after trading near $132 in recent sessions.
• The strongest bullish catalyst is accelerating AI-driven drug-discovery order momentum, supported by raised revenue guidance and a path toward positive adjusted EBITDA.
• The biggest obstacles are a loss-making business, an extremely stretched valuation, and the fact that the stock already trades well above even the most bullish analyst price target.
• Near-term resistance sits around the 52-week high near $155, while psychological and moving-average support zones lie near $108 and $100.
• Reaching $200 would require a roughly 50% advance from current levels and likely a meaningful re-rating of the shares.

Why Investors Are Watching the $200 Level

Twist Bioscience Corporation (TWST), a synthetic biology company that manufactures synthetic DNA using a proprietary silicon-based synthesis platform, has staged one of the most dramatic rallies in the biotechnology sector over the past year. After trading below $30 in late 2025, the shares have surged to roughly $132, briefly touching a 52-week high near $155 in late August. With that momentum, investors are naturally asking whether the stock can climb to the next psychologically significant milestone: $200 per share.

That level matters for a reason. It would mark a return toward the valuation the company commanded during the 2021 synthetic-biology boom, when the stock reached an all-time high of about $214. For many long-term holders, $200 represents a meaningful recovery target, but it would still require a gain of roughly 50% from current prices.

Current Market Position

Twist generates revenue from two primary product lines: next-generation sequencing (NGS) tools and synthetic DNA products such as custom genes, oligonucleotides, and protein solutions used in research and drug discovery. In its most recent fiscal quarter, revenue grew more than 20% year over year, and gross margin has climbed above 50%.

Despite that growth, the company remains firmly unprofitable, posting a trailing-twelve-month net loss of roughly $137 million. The shares carry a market capitalization near $9 billion against trailing revenue of about $432 million, implying a price-to-sales ratio near 20 times. The stock also has a beta well above 2, underscoring its extreme volatility relative to the broader market.

What Could Drive the Next Leg Higher

The central bull thesis is Twist's exposure to AI-enabled biology. Management has reported triple-digit growth in AI-driven drug-discovery orders and raised its full-year revenue guidance, while projecting positive adjusted EBITDA by late fiscal 2026 and for all of fiscal 2027. At its investor day, the company outlined a path toward roughly $1 billion in revenue by fiscal 2031.

Elevated short interest also adds fuel to the debate. Roughly 22% of shares outstanding were sold short as of mid-August, a level that could contribute to sharp upward moves if positive news forces short sellers to cover.

What Could Prevent the Move

The most significant obstacle is valuation. Even the most optimistic Wall Street analyst has a price target of $120, while the consensus sits near $98 to $105. That means the stock already trades above every published analyst target, and a move to $200 would require the market to assign a premium well beyond what professional forecasters currently model.

Fundamental math reinforces the challenge. At a $200 share price, Twist would carry a market value near $12.5 billion against roughly $432 million in trailing revenue, implying a price-to-sales multiple approaching 30 times. Reaching that level without further multiple expansion would require revenue to roughly double, a multi-year undertaking. Insider activity has also leaned toward selling, and the company remains cash-flow negative, leaving it exposed to broader risk-off sentiment in speculative growth names.

Analyst Opinions and Technical Levels

Wall Street remains broadly constructive on the stock's long-term story, with a consensus rating near a Moderate Buy and the majority of covering analysts at Buy or Overweight. However, their targets, ranging from roughly $36 to $120, sit well below the $200 question. That divergence suggests the stock's recent move has been driven less by earnings revisions and more by enthusiasm around AI-related biology themes.

From a technical perspective, the 52-week high near $155 acts as near-term resistance, with $150 serving as a psychological hurdle just below it. On the downside, the 50-day moving average near $108 and the $100 round-number level represent potential support zones. A sustained advance toward $200 would likely require the stock to first clear and hold above its recent highs, establishing a new base before attempting the next leg.

AI Daily Buy/Sell Signals

For traders monitoring volatile, fast-moving names like Twist Bioscience, tools that track changing conditions can help cut through the noise. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening allows. For investors watching whether TWST can sustain its momentum toward higher levels, automated signal monitoring offers a practical way to stay informed as conditions change.

Final Assessment

The $200 target is not impossible, but it is ambitious. The strongest support comes from genuine revenue acceleration, improving gross margins, and a credible path to profitability backed by surging AI-related order activity. Against that, the stock's valuation already exceeds every analyst target, the company remains unprofitable, and a move to $200 would require either a dramatic acceleration in revenue or a sustained expansion of an already elevated multiple.

Investors should monitor revenue guidance, the pace of AI-driven order growth, progress toward adjusted EBITDA, and the stock's ability to hold above key support levels. A decisive break and hold above the 52-week high would be an early sign that the $200 conversation is becoming more realistic; a failure to maintain support near $100 would suggest the rally is running ahead of the fundamentals. As always, the outcome will depend less on short-term momentum and more on whether Twist can convert its AI-enabled growth narrative into sustained financial results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations